Transglutaminase as a target for novel anti-filarial agents

被引:0
作者
Kapil Mehta
机构
[1] The University of Texas M.D. Anderson Cancer Center,Division of Bioimmunotherapy 60
关键词
Filariasis; transglutaminase; chemotherapy; cuticle; sheath;
D O I
10.1007/BF02873049
中图分类号
学科分类号
摘要
A rational approach for developing effective filaricides awaits greater knowledge on the biochemical pathways operating in filarial parasites. For example, metabolic pathways or key enzymes that are so pivotal to the parasite that their interruption or inhibition causes spontaneous death, could be exploited to develop effective chemotherapeutic agents. Similarly, developing a safe and nontoxic filaricidal will require precise understanding of whether or not the potential molecular target in the parasite is unique or at least different enough from the host system. Recently, we identified a novel transglutaminase enzyme (EC2.3.2.13; TGase) in filarial parasites that plays an important role during their normal growth and development. Based on these principles, TGase may serve as a new target for the development of effective chemotherapeutic agent and vaccine for controlling and preventing the infections caused by these parasites.
引用
收藏
页码:23 / 25
页数:2
相关论文
共 50 条
[21]   Potential of transglutaminase 2 as a therapeutic target [J].
Caccamo, Daniela ;
Curro, Monica ;
Ientile, Riccardo .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (09) :989-1003
[22]   Transglutaminase as a therapeutic target for celiac disease [J].
Sulic, Ana-Marija ;
Kurppa, Kalle ;
Rauhavirta, Tiina ;
Kaukinen, Katri ;
Lindfors, Katri .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (03) :335-348
[23]   ASSESSMENT OF THE POLYAMINE METABOLISM OF FILARIAL WORMS AS A TARGET FOR CHEMOTHERAPY [J].
MULLER, S ;
HUNTER, KJ ;
KONDUR, S ;
HELLMUND, C ;
FAIRLAMB, AH ;
WALTER, RD .
PARASITE, 1994, 1 :60-61
[24]   Transglutaminase 2 as a novel target in chronic kidney disease-Methods, mechanisms and pharmacological inhibition [J].
Prat-Duran, Judit ;
Pinilla, Estefano ;
Norregaard, Rikke ;
Simonsen, Ulf ;
Buus, Niels Henrik .
PHARMACOLOGY & THERAPEUTICS, 2021, 222
[25]   A novel transglutaminase activator forms a complex with type 1 transglutaminase [J].
Sturniolo, MT ;
Chandraratna, RAS ;
Eckert, RL .
ONCOGENE, 2005, 24 (18) :2963-2972
[26]   A novel transglutaminase activator forms a complex with type 1 transglutaminase [J].
Michael T Sturniolo ;
Roshantha A S Chandraratna ;
Richard L Eckert .
Oncogene, 2005, 24 :2963-2972
[27]   Transglutaminase 2 as a therapeutic target for neurological conditions [J].
Keillor, Jeffrey W. ;
Johnson, Gail V. W. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (09) :721-731
[28]   Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors [J].
Fell, Shaun ;
Wang, Zhuo ;
Blanchard, Andy ;
Nanthakumar, Carmel ;
Griffin, Martin .
AMINO ACIDS, 2021, 53 (02) :205-217
[29]   Wolbachia Ferrochelatase as a potential drug target against filarial infections [J].
Biney, Cephas ;
Graham, Grazia Edumaba ;
Asiedu, Ebenezer ;
Sakyi, Samuel Asamoah ;
Kwarteng, Alexander .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 122
[30]   Wolbachia bacteria of filarial nematodes in the pathogenesis of disease and as a target for control [J].
Taylor, MJ .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2000, 94 (06) :596-598